Low adherence to the herpes zoster vaccine in the United Kingdom raises alarm among health authorities

Serviço Nacional of Saúde (NHS) of Reino Unido faces a significant challenge in protecting the elderly population against shingles, a painful and potentially debilitating viral disease. Relatórios recent studies indicate that vaccination coverage is below expectations, especially among those who have just become eligible for the vaccine. Especialistas warn that the lack of adequate protection can result in an increase in serious cases and long-term complications.
Official data indicate that only a minority of citizens who turned 66 received the first dose of the Shingrix vaccine, offered free of charge by the public system. The situation is closely monitored by health security agencies, who seek to understand the reasons behind the low demand, even with the availability of the drug in local clinics and pharmacies.
Immunization is considered the main tool to prevent postherpetic neuralgia, a chronic condition that causes persistent nerve pain after skin lesions disappear. The British program uses the Shingrix vaccine, known for its high efficacy, greater than 90% in preventing the disease in healthy adults, being administered in two doses spaced a few months apart.
– The vaccine is mainly aimed at seniors aged 65 and over.
– Pessoas with severe immunosuppression are eligible from the age of 18.
– The complete vaccination schedule requires two doses to guarantee protection.
– The current low adherence worries managers about collective immunity.
Current scenario of vaccination rates
Surveys carried out until October 2025 show that coverage of the first dose among people aged 66 years old stagnated at 42.1%. Esse number reveals a considerable gap in protection for this age group, leaving more than half of the target audience exposed to the virus.
Among 71-year-olds, the immunization rate is slightly higher, reaching 53.5%, but still considered insufficient by health authorities to establish a robust epidemiological barrier. Adherence to the second dose, essential for the lasting effectiveness of the vaccine, has even lower rates.
British health authorities point out that the lack of awareness about the severity of the disease and occasional difficulties in accessing clinics may be contributing to these results. Continuous monitoring aims to identify critical regions where intervention needs to be intensified.
Expansion of eligibility criteria
The immunization program has undergone strategic reviews in recent years to expand access and protect more vulnerable citizens. Originalmente focused on people over 70, the NHS reduced the starting age to 65 from September 2023, following recommendations from Comitê Conjunto, Vacinação and Imunização. Essa change was based on evidence showing clear benefits in early prevention, before the immune system naturally weakens with advanced aging.
In addition to the age group, there was an important inclusion of clinical risk groups. Desde September 2025, all adults with severe immunosuppression, aged 18 and over, became eligible to receive the vaccine. Essa measure aims to protect cancer patients, transplant patients or those with autoimmune diseases, whose defense systems cannot contain the reactivation of the varicella-zoster virus with the same efficiency as healthy individuals.
Risks associated with the disease
Herpes zoster occurs due to the reactivation of the chickenpox virus, which remains latent in the body of those who had chickenpox in childhood. Quando the immune system fails to keep the virus under control, it multiplies again, causing inflammation in the nerves and skin.
Initial symptoms generally include tingling, intense local pain and fever, progressing to rashes that may appear on the trunk or face. In more serious cases, the disease can affect vision or hearing, depending on the nerves involved.
Medical reports indicate that around 20% of patients develop chronic pain that persists for months or years, drastically impacting quality of life and mobility. Essa complication is more common in the elderly, making preventive vaccination an absolute priority.
For immunocompromised patients, the risk of secondary complications, such as bacterial infections in the lesions and neurological problems, is significantly higher. Vaccination works not only to prevent an outbreak, but to reduce the severity of symptoms if the disease does occur.
Strategies to expand reach
To reverse the low coverage situation, the NHS plans a series of integrated actions that involve education and facilitating access. Campanhas information is being designed to clarify doubts about the safety of the vaccine and highlight the benefits of prevention, using partnerships with community organizations and sending digital reminders via health apps. Estudos locations indicate that the possibility of vaccination in pharmacies without the need for prior scheduling significantly increases adherence, a strategy that should be reinforced in urban and rural areas. Além In addition, the integration of the herpes zoster vaccine with other campaigns, such as the flu, is seen as a logistical opportunity to optimize patients’ visits to health units.
Vaccine protocols and technology
The vaccine used, Shingrix, is a non-live recombinant type, which represents an advance in safety for immunocompromised patients compared to previous versions. Sua formulation contains specific antigens that stimulate a robust and long-lasting immune response, as proven in extensive clinical trials.
Health professionals recommend that, for patients who will begin immunosuppressive treatments, vaccination ideally begins one month before therapies. Strict adherence to the interval between the two doses is emphasized in technical guidelines to ensure maximum efficacy promised by studies.
Monitoring and future of the program
Periodic reports, such as the one published in February 2026, continue to guide public policy and the allocation of NHS resources. The expectation is that the program will gradually expand over the decade, incorporating new cohorts as system capacity allows and based on real-life data.







